Pheromone traps for monitoring Plodia interpunctella (Hübner) (Lepidoptera: Pyralidae) in the presence of mating disruption

High-dose pheromone lures have proved useful for monitoring some lepidopteran pests in the presence of mating disruption, but not others. We performed experiments in commercial and pilot scale facilities to examine the effect of pheromone dose on detection of Indianmeal moth, Plodia interpunctella (Lepidoptera: Pyralidae), in the presence of mating disruption. When P. interpunctella males were released into 1000 m3 rooms containing traps baited with 0, 1, or 10 mg (Z,E)-9,12-tetradecadienyl acetate (Z9,E12-14:Ac), traps containing 10 mg captured more than those baited with 1 mg in both the presence and absence of mating disruption. Traps baited with 1 mg captured fewer males in the presence of mating disruption than in its absence, but the opposite was observed with traps baited with 10 mg. When males released into 73 m3 rooms were exposed sequentially to blank traps, traps baited with unmated females, and traps baited with 0.1 mg and then 1.0 mg Z9, E12-14:Ac in the presence or absence of mating disruption, 92% of trapped males were captured in female-baited traps in the absence of mating disruption, whereas in the presence of mating disruption 72% of males captured were caught in synthetic pheromone traps. These data suggest that pheromone lures can be used for monitoring P. interpunctella in the presence of mating disruption. Implications of these data for mass trapping are also discussed. Keywords: Plodia interpunctella, Mating disruption, Monitoring, Pheromone lures, Mass trappin

Immune checkpoint inhibitor-associated myocarditis:Case reports and a review of the literature

Immune checkpoint inhibitors (ICIs) are increasingly recognised to effectuate long-lasting therapeutic responses in solid tumours. However, ICI therapy can also result in various immune-related adverse events, such as ICI-associated myocarditis, a rare but serious complication. The clinical spectrum is wide and includes asymptomatic patients and patients with fulminant heart failure, making it challenging to diagnose this condition. Furthermore, the optimal diagnostic algorithm and treatment of ICI-associated myocarditis is unknown. In this review, we describe two cases on both ends of the spectrum and discuss the challenges in recognising, diagnosing and treating ICI-associated myocarditis

Attractiveness of a Four-component Pheromone Blend to Male Navel Orangeworm Moths

The attractiveness to male navel orangeworm moth, Amyelois transitella, of various combinations of a four-component pheromone blend was measured in wind-tunnel bioassays. Upwind flight along the pheromone plume and landing on the odor source required the simultaneous presence of two components, (11Z,13Z)-hexadecadienal and (3Z,6Z,9Z,12Z,15Z)-tricosapentaene, and the addition of either (11Z,13Z)-hexadecadien-1-ol or (11Z,13E)-hexadecadien-1-ol. A mixture of all four components produced the highest levels of rapid source location and source contact. In wind-tunnel assays, males did not seem to distinguish among a wide range of ratios of any of the three components added to (11Z,13Z)-hexadecadienal. Dosages of 10 and 100 ng of the 4-component blend produced higher levels of source location than dosages of 1 and 1,000 ng

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

SU5416 (Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone; semaxanib) is a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR)2. A Phase I dose escalation study was performed. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used as a pharmacodynamic assessment tool. In all, 27 patients were recruited. SU5416 was administered twice weekly by fixed rate intravenous infusion. Patients were treated in sequential cohorts of three patients at 48, 65, 85 110 and 145 mg m−2. A further dose level of 190 mg m−2 after a 2-week lead in period at a lower dose was completed; thereafter, the cohort at 145 mg m−2 was expanded. SU5416 showed linear pharmacokinetics to 145 mg m−2 with a large volume of distribution and rapid clearance. A significant degree of interpatient variability was seen. SU5416 was well tolerated, by definition a maximum-tolerated dose was not defined. No reproducible changes were seen in DCE-MRI end points. Serial assessments of VEGF in a cohort of patients treated at 145 mg m−2 did not show a statistically significant treatment-related change. Parallel assessments of the impact of SU5416 on coagulation profiles in six patients showed a transient effect within the fibrinolytic pathway. Clinical experience showed that patients who had breaks of therapy longer than a week could not have treatment reinitiated at a dose of 190 mg m−2 without unacceptable toxicity. The 145 mg m−2 dose level is thus the recommended dose for future study

Simulating secondary organic aerosol from missing diesel-related intermediate-volatility organic compound emissions during the Clean Air for London (ClearfLo) campaign

We present high-resolution (5g kmg × g 5g km) atmospheric chemical transport model (ACTM) simulations of the impact of newly estimated traffic-related emissions on secondary organic aerosol (SOA) formation over the UK for 2012. Our simulations include additional diesel-related intermediate-volatility organic compound (IVOC) emissions derived directly from comprehensive field measurements at an urban background site in London during the 2012 Clean Air for London (ClearfLo) campaign. Our IVOC emissions are added proportionally to VOC emissions, as opposed to proportionally to primary organic aerosol (POA) as has been done by previous ACTM studies seeking to simulate the effects of these missing emissions. Modelled concentrations are evaluated against hourly and daily measurements of organic aerosol (OA) components derived from aerosol mass spectrometer (AMS) measurements also made during the ClearfLo campaign at three sites in the London area. According to the model simulations, diesel-related IVOCs can explain on average ∼30g % of the annual SOA in and around London. Furthermore, the 90th percentile of modelled daily SOA concentrations for the whole year is 3.8g μg-3, constituting a notable addition to total particulate matter. More measurements of these precursors (currently not included in official emissions inventories) is recommended. During the period of concurrent measurements, SOA concentrations at the Detling rural background location east of London were greater than at the central London location. The model shows that this was caused by an intense pollution plume with a strong gradient of imported SOA passing over the rural location. This demonstrates the value of modelling for supporting the interpretation of measurements taken at different sites or for short durations

Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [68Ga]Ga-DOTA-E-[c(RGDfK)]2 PET/CT

n/

Angiogenesis inhibitors in clinical development; where are we now and where are we going?

Angiogenesis is crucial for tumour growth and the formation of metastases. Various classes of angiogenesis inhibitors that are each able to inhibit one of the various steps of this complex process can be distinguished. Results from clinical studies with these agents are summarised. In general, it has been shown that most angiogenesis inhibitors can be safely administered, but that tumour regressions are rare. Combining angiogenesis inhibitors with cytotoxic chemotherapy can enhance anticancer activity. Recently, some promising data with regard to clinical efficacy have been presented. While performing clinical studies with angiogenesis inhibitors, defining biological activity is crucial, but thus far no validated techniques are available. It is conceivable that in the near future various classes of angiogenesis inhibitors will be combined in an attempt to further improve antiangiogenic and anticancer activity

Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675)

Introduction: To compare neurocognitive functioning in patients with SCLC who received prophylactic cranial irradiation (PCI) with or without hippocampus avoidance (HA). Methods: In a multicenter, randomized phase 3 trial (NCT01780675), patients with SCLC were randomized to standard PCI or HA-PCI of 25 Gy in 10 fractions. Neuropsychological tests were performed at baseline and 4, 8, 12, 18, and 24 months after PCI. The primary end point was total recall on the Hopkins Verbal Learning Test-Revised at 4 months; a decline of at least five points from baseline was considered a failure. Secondary end points included other cognitive outcomes, evaluation of the incidence, location of brain metastases, and overall survival. Results: From April 2013 to March 2018, a total of 168 patients were randomized. The median follow-up time was 26.6 months. In both treatment arms, 70% of the patients had limited disease and baseline characteristics were well balanced. Decline on the Hopkins Verbal Learning Test-Revised total recall score at 4 months was not significantly different between the arms: 29% of patients on PCI and 28% of patients on HA-PCI dropped greater than or equal to five points (p = 1.000). Performance on other cognitive tests measuring memory, executive function, attention, motor function, and processing speed did not change significantly different over time between the groups. The overall survival was not significantly different (p = 0.43). The cumulative incidence of brain metastases at 2 years was 20% (95% confidence interval: 12%-29%) for the PCI arm and 16% (95% confidence interval: 7%-24%) for the HA-PCI arm. Conclusions: This randomized phase 3 trial did not find a lower probability of cognitive decline in patients with SCLC receiving HA-PCI compared with conventional PCI. No increase in brain metastases at 2 years was observed in the HA-PCI arm. (C) 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved

Emission ensemble approach to improve the development of multi-scale emission inventories

Many studies have shown that emission inventories are one of the inputs with the most critical influences on the results of air quality modelling. Comparing emission inventories among themselves is, therefore, essential to build confidence in emission estimates. In this work, we extend the approach of Thunis et al. (2022) to compare emission inventories by building a benchmark that serves as a reference for comparisons. This benchmark is an ensemble that is based on three state-of-the-art EU-wide inventories: CAMS-REG, EMEP and EDGAR. The ensemble-based methodology screens differences between inventories and the ensemble. It excludes differences that are not relevant and identifies among the remaining ones those that need special attention. We applied the ensemble-based screening to both an EU-wide and a local (Poland) inventory. The EU-wide analysis highlighted a large number of inconsistencies. While the origin of some differences between EDGAR and the ensemble can be identified, their magnitude remains to be explained. These differences mostly occur for SO2 (sulfur oxides), PM (particulate matter) and NMVOC (non-methane volatile organic carbon) for the industrial and residential sectors and reach a factor of 10 in some instances. Spatial inconsistencies mostly occur for the industry and other sectors. At the local scale, inconsistencies relate mostly to differences in country sectorial shares that result from different sectors/activities being accounted for in the two types of inventories. This is explained by the fact that some emission sources are omitted in the local inventory due to a lack of appropriate geographically allocated activity data. We identified sectors and pollutants for which discussion between local and EU-wide emission compilers would be needed in order to reduce the magnitude of the observed differences (e.g. in the residential and industrial sectors). The ensemble-based screening proved to be a useful approach to spot inconsistencies by reducing the number of necessary inventory comparisons. With the progressive resolution of inconsistencies and associated inventory improvements, the ensemble will improve. In this sense, we see the ensemble as a useful tool to motivate the community around a single common benchmark and monitor progress towards the improvement of regionally and locally developed emission inventories.</p